BrUOG-H-N-229-RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer: A PHASE I STUDY- Novartis CRAD001CUS134T.

Trial Profile

BrUOG-H-N-229-RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer: A PHASE I STUDY- Novartis CRAD001CUS134T.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2015

At a glance

  • Drugs Everolimus (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2012 Planned end date changed from 1 Jun 2012 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 11 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top